title: Drug interactions with fibric acids.
abstract: Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance. The pharmacological properties and effects of these drugs which pertain to their potential for drug interactions, are: (a) a very high binding affinity to plasma proteins, especially albumin; (b) the changes produced in vitamin K kinetics; (c) endoplasmic reticulum hyperplasia; (d) induction of cytochrome P450; (e) changes in xenobiotic-metabolizing enzymes; (f) their capability to have a direct effect on carbohydrate metabolism and/or regulation; and (g) potential pharmacokinetic interactions with antidiabetic drugs. Other types of interactions may affect the safety and/or the therapeutic efficacy of fibrates. These interactions are not necessarily risky, but may be important in the long term. Other clinically relevant interactions with less commonly used drugs have been described. Fibrates will continue to be used because they have proved to be safe and effective in correcting many types of dyslipidemia by reducing serum levels of total cholesterol and triglycerides and by increasing high density lipoprotein cholesterol. Furthermore, they have been proven to decrease morbidity and morality from coronary heart disease. Therefore, awareness of their potential drug interactions is most relevant to their safe clinical therapeutic use.
authors: Division of Clinical Pharmacology, University of Kansas Medical Center, KU Hospital, Kansas City 66160-7374.
authors: A
authors: A
authors: Lozada
authors: C A
authors: CA
authors: Dujovne
mesh_terms: D000925:Anticoagulants / Q000493:pharmacokinetics; D001629:Bezafibrate / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002994:Clofibrate / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000493:pharmacokinetics; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality; D004347:Drug Interactions; D011345:Fenofibrate / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D058607:Fibric Acids; D015248:Gemfibrozil / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics; D000960:Hypolipidemic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood
chemical_list: D000925:Anticoagulants; D003276:Contraceptives, Oral; D058607:Fibric Acids; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D008055:Lipids; D002995:Clofibric Acid; C019304:ciprofibrate; D002994:Clofibrate; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate